Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 8/20 | 1.00 |
| ▸ | MMP2 | P08253 | 7/20 | 1.00 |
| ▸ | MMP1 | P03956 | 1/20 | 1.00 |
| ▸ | MMP9 | P14780 | 1/20 | 1.00 |
| ▸ | MMP13 | P45452 | 1/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.82 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.82 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.57 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.57 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7046816 | 0.93 | MMP3 (0.92) | MMP3MMP2MMP1MMP9MMP13 | |
| SCHEMBL6386979 | 0.91 | MMP3 (1.00) | MMP3MMP2MMP1MMP9MMP13 | |
| SCHEMBL4741061 | 0.90 | HDAC1 (1.00) | MMP3MMP2MMP1MMP9MMP13 | |
| SCHEMBL6390923 | 0.90 | HDAC1 (1.00) | MMP3MMP2MMP1MMP9MMP13 | |
| SCHEMBL7043273 | 0.84 | MMP3 (0.77) | MMP3MMP2MMP1MMP9MMP13 | |
| SCHEMBL7044763 | 0.83 | MMP3 (1.00) | MMP3MMP2MMP1MMP9MMP13 | |
| SCHEMBL16380470 | 0.83 | MMP2 (1.00) | MMP3MMP2MMP1MMP9MMP13 | |
| SCHEMBL7043153 | 0.82 | MMP3 (0.73) | MMP3MMP2MMP1MMP9MMP13 | |
| SCHEMBL16380448 | 0.81 | MMP2 (0.74) | MMP3MMP2MMP1MMP9MMP13 | |
| SCHEMBL7046807 | 0.81 | MMP3 (0.74) | MMP3MMP2MMP1MMP9MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0874808-B1 | BIPHENYL HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LAB (US) | 2003-04-09 | — | — | EP | claimed |
| EP-0874808-A1 | BIPHENYL HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES | Abbott Laboratories (US) | 1998-11-04 | — | — | EP | claimed |
| WO-1997018188-A1 | BIPHENYL HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LABORATORIES (US) | 1997-05-22 | — | — | WO | claimed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| EP-2282719-B1 | COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS | REVALESIO CORP (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-2282719-B1 | COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS | REVALESIO CORP (US) | 2018-05-30 | — | — | EP | disclosed |
| US-9745567-B2 | Compositions and methods for treating multiple sclerosis | REVALESIO CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-9523090-B2 | Compositions and methods for treating inflammation | REVALESIO CORPORATION (US) | 2016-12-20 | — | — | US | disclosed |
| US-8828977-B2 | Method of treating a subject suffering from degenerative disc disease using a matrix metalloprotease inhibitor | DISCOGEN, LLC (US) | 2014-09-09 | — | — | US | disclosed |
| US-20100004189-A1 | COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS | REVALESIO CORPORATION (US) | 2010-01-07 | — | — | US | disclosed |
| EP-1986657-A2 | METHOD OF TREATING A SUBJECT SUFFERING FROM DEGENERATIVE DISC DISEASE USING A MATRIX METALLOPROTEASE INHIBITOR | Discogen, LLC (US) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007098099-A2 | METHOD OF TREATING A SUBJECT SUFFERING FROM DEGENERATIVE DISC DISEASE USING A MATRIX METALLOPROTEASE INHIBITOR | DISCOGEN, LLC (US) | 2007-08-30 | — | — | WO | disclosed |
| US-20070197550-A1 | Histone deacetylase inhibitors for enhancing activity of antifungal agents | 92229129 QUEBEC INC. (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070197550-A1 | Histone deacetylase inhibitors for enhancing activity of antifungal agents | 92229129 QUEBEC INC. (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070190149-A1 | Method of treating a subject suffering from degenerative disc disease using a matrix metalloprotease inhibitor | DISCOGEN, LLC | 2007-08-16 | — | — | US | disclosed |
| WO-2007072179-A2 | HISTONE DEACETYLASE INHIBITORS FOR ENHANCING ACTIVITY OF ANTIFUNGAL AGENTS | METHYLGENE, INC. (CA) | 2007-06-28 | — | — | WO | disclosed |
| EP-0874808-B1 | BIPHENYL HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LAB (US) | 2003-04-09 | — | — | EP | disclosed |
| US-5665777-A | ANTIINFLAMMATORY AGENTS | ABBOTT LABORATORIES (US) | 1997-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197550-A1 | Histone deacetylase inhibitors for enhancing activity of antifungal agents | HDAC1, HDAC5, HDAC7 | MMP3 644/4885MMP2 1446/4885MMP1 1803/4885 |
| US-20100004189-A1 | COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS | CFTR, GJB2, KRAS | MMP3 3582/4885MMP2 2983/4885MMP1 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.